Clinical trials

We are dedicated to providing our patients with the most up-to-date treatment options. Our physicians actively seek out new options in treating retinal diseases by participating in cutting-edge clinical research trials. SCRC has enrolled hundreds of patients in studies that have helped shape the course and treatment plan for multiple retinal diseases, such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion and proliferative diabetic retinopathy.

We are dedicated to providing our patients with the most up-to-date treatment options. Our physicians actively seek out new options in treating retinal diseases by participating in cutting-edge clinical research trials. SCRC has enrolled hundreds of patients in studies that have helped shape the course and treatment plan for multiple retinal diseases, such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion and proliferative diabetic retinopathy.

Less

The following research trials are currently offered at South Coast Retina Center:

The following research trials are currently offered at South Coast Retina Center:

Less

Protocol AC

We are working with the Diabetic Retinopathy Clinical Research network (DRCR) to compare the efficacy between two treatments paths in patients with diabetic macular edema and moderate vision loss. The first treatment arm examines patients who have received Eylea injections from the start of their diagnosis. The second treatment arm examines patients who have received Avastin injections from the start of their diagnosis and then switched over to Eylea injections.

Protocol AC

We are working with the Diabetic Retinopathy Clinical Research network (DRCR) to compare the efficacy between two treatments paths in patients with diabetic macular edema and moderate vision loss. The first treatment arm examines patients who have received Eylea injections from the start of their diagnosis. The second treatment arm examines patients who have received Avastin injections from the start of their diagnosis and then switched over to Eylea injections.

Less

Rhine 

 We are working with Genentech Roche to compare the efficacy and safety of Faricimab, a new anti-VEGF injection, with Eylea, one of the current standard anti-VEGF injections, in patients with age-related macular degeneration. Faricimab is the first antibody that is anti-VEGF and anti-Ang-2 designed for intravitreal use.



VEGF, also known as Vascular Endothelial Growth Factor, is a molecule that causes the growth of leaky blood vessels. Anti-VEGF medications help stop the growth of new blood vessels. Ang-2, also known as angiogenesis 2, promotes destabilization of blood vessels leading to leakage and inflammation. Anti-Ang 2 stabilizes the blood vessels by reducing leakage and inflammation.

Rhine 

 We are working with Genentech Roche to compare the efficacy and safety of Faricimab, a new anti-VEGF injection, with Eylea, one of the current standard anti-VEGF injections, in patients with age-related macular degeneration. Faricimab is the first antibody that is anti-VEGF and anti-Ang-2 designed for intravitreal use. VEGF, also known as Vascular Endothelial Growth Factor, is a molecule that causes the growth of leaky blood vessels. Anti-VEGF medications help stop the growth of new blood vessels. Ang-2, also known as angiogenesis 2, promotes destabilization of blood vessels leading to leakage and inflammation. Anti-Ang 2 stabilizes the blood vessels by reducing leakage and inflammation.

Less

Tenaya 

 We are working with Genentech Roche to compare the efficacy and safety of Faricimab, a new anti-VEGF injection, with Eylea, one of the current standard anti-VEGF injections, in patients with diabetic macular edema. Faricimab is the first antibody that is anti-VEGF and anti-Ang-2 designed for intravitreal use.
VEGF, also known as Vascular Endothelial Growth Factor, is a molecule that causes the growth of leaky blood vessels. Anti-VEGF medications help stop the growth of new blood vessels. Ang-2, also known as angiogenesis 2, promotes destabilization of blood vessels leading to leakage and inflammation. Anti-Ang 2 stabilizes the blood vessels by reducing leakage and inflammation.

Tenaya 

 We are working with Genentech Roche to compare the efficacy and safety of Faricimab, a new anti-VEGF injection, with Eylea, one of the current standard anti-VEGF injections, in patients with diabetic macular edema. Faricimab is the first antibody that is anti-VEGF and anti-Ang-2 designed for intravitreal use. VEGF, also known as Vascular Endothelial Growth Factor, is a molecule that causes the growth of leaky blood vessels. Anti-VEGF medications help stop the growth of new blood vessels. Ang-2, also known as angiogenesis 2, promotes destabilization of blood vessels leading to leakage and inflammation. Anti-Ang 2 stabilizes the blood vessels by reducing leakage and inflammation.

Less

Sequoia 

 We are working with Allergan to compare the efficacy and safety of Abicipar, a new anti-VEGF injection, with Lucentis, one of the current standard anti-VEGF injections,in patients with age-related macular edema. Sequoia's clinical hypothesis is that Abicipar will require less frequent injections, in comparison to Lucentis, which would remove a significant treatment burden on patients and it would decrease the risk of complications associated with frequent intravitreal injections.



 If you are interested in participating in any of the clinical trials offered at South Coast Retina Center, please contact our office at 562-984-7024 and select

Option 6. 

Sequoia 

 We are working with Allergan to compare the efficacy and safety of Abicipar, a new anti-VEGF injection, with Lucentis, one of the current standard anti-VEGF injections,in patients with age-related macular edema. Sequoia's clinical hypothesis is that Abicipar will require less frequent injections, in comparison to Lucentis, which would remove a significant treatment burden on patients and it would decrease the risk of complications associated with frequent intravitreal injections.



 If you are interested in participating in any of the clinical trials offered at South Coast Retina Center, please contact our office at 562-984-7024 and select

Option 6. 

Less